

Improving Kidney Health Outcomes
Lead Program: Varoglutamstat in Diabetic Kidney Disease

December 2024

Vivoryon Therapeutics N.V.

Important Notice and Disclaimer

This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decision.

This document and its contents may not be reproduced, redistributed, published or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. Failure to comply with these restrictions may constitute a violation of applicable securities laws. By accepting and reading this document, you will be deemed to agree not to disclose, reproduce or otherwise distribute any information contained herein.

Certain information contained in this document has been obtained from published and non-published sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or its affiliates, directors, officers, employees, members, partners, shareholders or agents make any representation or warranty with respect to or assume any responsibility for the accuracy of such information, and such information has not been independently verified by the Company.

Certain statements contained in this document constitute forward-looking statements, estimates, predictions, influences and projections which are subject to risks and uncertainties and may reflect various assumptions, which may or may not prove to be correct. These forward-looking statements include information about possible or assumed future results of the Company’s business, financial condition, results of operations, liquidity, business strategy, management plans and objectives for future operations. In particular, the words “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate” and “potential,” or other similar expressions are intended to identify forward-looking statements. Forward-looking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various risk factors and uncertainties including without limitation in relation to: the effectiveness of our main product candidate, and our ability to commercialize it if the regulatory approval is obtained; our ability to explore other potential fields of application of our product candidates and benefits of combination therapies between our product candidates and other products; our ability to compete and conduct our business in the future; our ability to expend our limited resources and to obtain funding for our operations necessary to continue as a going concern or to complete further development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by applicable law.

Vivoryon: Poised to improve kidney health with varoglutamstat's novel mechanism of action and breakthrough clinical results

- Strong scientific base; novel MoA (QPCT/L inhibition); pE-CCL2 data confirms target engagement
- Two independent Phase 2 studies[1]; compelling long-term kidney function improvement
- Extensive safety data package for varoglutamstat with convenient dose escalation scheme
- Focused development plan for significant commercial opportunity in DKD and beyond
- Additional potential orphan indications e.g. Alport Syndrome / Fabry Disease
- Composition of matter patent protection[2] expected to 2044+
- Cash runway into Q3 2025; actively pursuing funding and BD opportunities

[1] VIVIAD and VIVA-MIND Phase 2 studies in early AD included prospectively defined measures of kidney function; [2] Current composition of matter patent to 2031 with additional potential for Hatch-Waxman extension of up to 5 years, new patent filings being evaluated.

Groundbreaking discovery: Inhibition of QPCTL reduces kidney inflammation and fibrosis, and improves kidney function

Pro-inflammatory and fibrotic peptides require pyroglutamate formation at N-terminal for full potency



QPCTL inhibition leads to reduction in potent pro-inflammatory and fibrotic peptides

Pyroglutamate formation (pE-formation) is exclusively catalyzed by QPCTL (iso-glutaminyl cyclase enzyme)

Inflammation	
pE-CCL2	↓
IFNγ	↓
TNFα	↓

Fibrosis	
Collagen 3	↓
α-SMA	↓
CX3CL1	↓

Kidney function	
eGFR	↑
Urea	↓
Cystatin C	↓

Kehlen et.al. Biosci Rep, 2017; Cynis et.al. EMBO, 2011; Cynis et al, Int. J Exp Path, 2013; Kanemitsu et al., 2021; Vivoryon company data, 2024; pE-CCLx – other potential pE chemokynes; Notes: Graphic is for illustrative purposes only.

Robust research supports development of QPCTL inhibitors in inflammatory and fibrotic kidney and liver disorders

Inflammation/kidney disease publications past 40 years*



*NIH/NCBI PubMed

Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury

Baeck et. al. 2012

N-terminal pyroglutamate formation in CXC3CL1 is essential for its full biologic activity

Kehlen et. al. 2017

Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice

Cynis et al., 2013

Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ259 is a novel and effective approach for glomerulonephritis in chronic kidney disease

Kanemitsu et. al. 2021

- Discovered and established pE-CCL2 as direct biomarker for QPCTL engagement
- Dose-dependent decrease of pE-CCL2 levels directly correlates with eGFR improvement

Cynis et.al. Int, J of Exp Pathol, 2013; Baeck et.al., Gut, 2012; Chang et.al. Int J Mol Sci., 2020; Kanemitsu et al., Naunyn Schmiedebergs Arch Pharmacol, 2021; Kehlen et al, Biosci Rep, 2017

VIVIAD: Breakthrough clinical results show statistically significant improvement in prospectively defined eGFR over two years

Validated regulatory primary endpoint

All subjects
Change in eGFR over time
Slope analysis





Diabetes
Change in eGFR over time
Slope analysis



Protocol for VIVIAD Phase 2b in early AD included investigation of kidney function to explore role of QPCTL inhibition; eGFR: estimated glomerular filtration rate based on creatinine, calculated using modification of diet in renal disease (MDRD) method, creatinine measured at 12-week intervals; Treatment effect: difference between eGFR slope in varoglutamstat-treated patients vs. placebo

VIVIAD: Consistency of results using diverse and validated methods for eGFR assessment

Sensitivity analysis: baseline adjusted treatment effect of varoglutamstat versus placebo



* significant difference (with p<0.05) ** significant difference (with p<0.01) *** significant difference (with p<0.001) **** significant difference (with p<0.0001)

CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration); eGFR assessed by Cystatin C and additional; Creatinine measurement (Atellica CH analyser)

VIVA-MIND: Statistically significant and clinically meaningful improvement vs. placebo in kidney function measured by eGFR (total population; MDRD)



Average improvement across all visits and all patients > 4mL/min/1.73m²



Effect size in the first 16 weeks of treatment approx. 3mL/min/1.73m² and between 24 and 72 weeks above 5mL/min/1.73m²

Placebo N=57, Varoglutamstat 600mg BID N=52

Calculations based on weighted average change from baseline

ª *Corrected from the previously reported p<0.001; More information on VIVA-MIND Phase 2 study at clinicaltrials.gov ID NCT03919162*

eGFR Results Comparison VIVA-MIND – VIVIAD

VIVA-MIND



VIVIAD



eGFR improvement of varoglutamstat versus placebo was consistent and statistically significant and clinically meaningful in both studies

*Data includes all patients and all visits with data in the observation period; * Periods adjusted to slower dose escalation and longer treatment duration in VIVIAD; MDRD calculation for eGFR, effect size calculated as weighted average; [a] Corrected from the previously reported p<0.001*

VIVIAD: Excellent safety profile consistent across two years of study duration

VIVIAD Phase 2b study
% of patients with at least one TEAE[1]



[1] % of patients with at least one Treatment-Emergent Adverse Events (TEAE) in a System Organ Class, lists only occurrence > 5% in the total population. Diabetes subgroup: patients having at baseline either medical history of diabetes (type 1 or 2) and/or comedication with drugs used in diabetes and/or untreated with a HbA1c > 6.5%.

VIVA-MIND: No new safety signals identified in second Phase 2 study

VIVA-MIND Phase 2 study			
Adverse event category (%)	Varoglutamstat (N=53)*	Placebo (N=56)*	Overall (N=109)
any TEAE	84.9	78.6	81.7
any related TEAE	30.2	32.1	31.2
TEAE by severity			
mild	26.4	41.1	33.9
moderate	47.2	28.6	37.6
severe	11.3	8.9	10.1
serious TEAE	15.1	8.9	11.9
related serious TEAE	0	1.8	0.9
TEAE leading to any study drug dose modification (excluding discontinuation)	5.7	7.1	6.4
TEAE leading to study drug discontinuation	7.5	3.6	5.5
TEAE leading to death[1]	1.9	0	0.9

Extensive safety package
(# / duration)

Pharmacology / Phase 1

- Phase 1 study: large trial with 205 subjects
- Human ADME / mass balance study completed

Phase 2 double-blind, placebo-controlled

- Phase 2a study: 120 patients, 12 weeks
- VIVIAD Phase 2b study: 259 patients, avg. treatment duration ~80 weeks
- VIVA-MIND Phase 2 study: 109 patients treated, avg. treatment duration ~46 weeks

[1] One patient died after a head injury from a fall and the patient had a patient's provision to not resuscitate. A second patient had surgery for gastrointestinal bleeding after stopping study medication and died from complications of the surgery several weeks later. The deaths were considered not / unlikely related to varoglutamstat – the DSMB recommended continuation of study without changes after occurrence of these events during the study.

TEAE: Treatment emergent adverse events occurring during the treatment period; table does not include events occurring after end of treatment (EOT);
** TEAEs are for Safety Analysis population which included patients who received ≥1 dose of varoglutamstat 600mg; the varoglutamstat arm includes one placebo patient who was identified as receiving a single dose of varoglutamstat in error and this person has been allocated to the varoglutamstat arm for Safety Analysis accordingly*

Clear dose-finding results strongly correlated with MoA and biomarker

Reduction of pE-CCL2 in VIVIAD correlates with improvement of eGFR

Varoglutamstat effect on kidney function outcomes
(total population; change in eGFR over time (MDRD)[1])



Median reduction in pE-CCL2 levels at week 48 compared to baseline with varoglutamstat
(total population)



[1] *Chart shows change in eGFR (estimated glomerular filtration rate) over time based on creatinine and calculated using modification of diet in renal disease (MDRD) method*

Summary of kidney function data from varoglutamstat Phase 2 program

- ✓ Two double blind placebo-controlled studies - one conducted in Europe and one in US - showed consistent statistically significant and clinically meaningful improvement of eGFR for varoglutamstat versus placebo
- ✓ In both studies eGFR was improved above baseline and stabilized across the whole treatment period of 96 weeks (VIVIAD) and 72 weeks (VIVA-MIND)
- ✓ The results provide robust evidence of a treatment benefit
- ✓ Good safety results in VIVA-MIND with the accelerated dose escalation scheme provide pathway for a convenient and commercially viable dosing schedule
- ✓ VIVA-MIND results fully support the sample size planning with 120 or fewer patients and previously communicated target effect size of 5mL/min/1.73m^2 for visits between week 24 and 72 for the planned Phase 2 study in DKD patients
- ◆ Analysis of VIVA-MIND data will continue

Outstanding commercial potential: Currently available, highly successful medicines only slow disease progression in DKD



SGLTi eGFR (compiled)[4]



Semaglutide FLOW trial



[1] Perkovic et al., N Engl J Med, 2019; [2] Heerspink et al. N Engl J Med, 2020; [3] Perkovic et al., N Engl J Med, 2024; [4] schematic based on Costanzo et al., Int. J. Mol. Sci. 2023; SGLT2 – sodium glucose cotransporter-2 inhibitor class; GLP-1 Glucagon-like peptide class (semaglutide is a GLP-1 receptor agonist); QPCT/L – varoglutamstat inhibits the glutaminyl cyclases QPCT and QPCTL; Note: Graphics and charts are for illustrative purposes, not intended to be direct comparisons between studies

DKD[1] is the leading cause of end stage kidney disease (ESKD)

Inflammation and fibrosis are key underlying pathways in DKD

Diabetes is a leading cause of end-stage kidney disease[2]



Diabetes is a significant and growing global challenge

(adults aged 20-79 years with diabetes, worldwide)[3]





~40%

of people with diabetes may develop diabetic kidney disease (DKD)[4]

1 in 10

people with diabetes may end up with end-stage kidney disease[4]

[1] Diabetic Kidney Disease (DKD): typically, DKD is defined by the presence of CKD characterized by persistently (≥ 3 months) elevated urinary albumin excretion (albumin-to-creatine ratio [ACR] ≥30 mg/g) and/or low eGFR (< 60mL/min/1.73 m²) in a person with diabetes (Levin et al., Kidney Int. Suppl. 2013, KDIGO group); [2] U.S. Renal Data System; [3]International Diabetes Federation (IDF) Atlas 2021; [4]Qazi et al., EMJ Nephrol, 2022.

Planned Phase 2 study in stage 3b/4 DKD on top of standard of care[1]

Draft study design, with anticipated interim analysis at 15 months after study start

Enrollment:

- Patients: Diabetes patients with CKD 3b/4 eGFR
- Number of patients: up to 120
- Regions: U.S. and Western Europe

Draft design:

- Double-blind placebo-controlled
- Powered to confirm effect size of at least 3.5mL/min eGFR slope; 80% power to detect a difference of 5mL/min eGFR slope

Duration/potential costs:

- Interim: until confirmation of effect size, ~15 months (~ 60 patients)
- Full: study completion approx. 2.5 yrs; typical trial cost approx. EUR 10 – 12m [2]



[1] *Clinical trial subject to further funding / partnership;*
[2] *Based on typical industry costs for Phase 2 in similar indications*

Vivoryon: A history of groundbreaking discoveries and developments



A trusted company: Senior management team with a strong track record

Executive Directors

Frank Weber, MD
Chief Executive Officer

InterMune® · Merck · ZBiotech Zambon Biotech

Anne Doering, CFA
Chief Financial Officer

BioNTech · Merck · Franklin Templeton

Michael Schaeffer, PhD
Chief Business Officer

Sareen · Crelux a WuXi AppTec company · Crenano

Non-executive Directors

Erich Platzer, MD, PhD
Chairman of the Board

Charlotte Lohmann

Claudia Riedl, PhD
Chair Audit Committee

Samir Shah, MD

Decades of collective experience in biopharma industry, e.g.:

First approved drug in pulmonary fibrosis

Successful development of biomarker driven oncology & diabetes programs

M&A and business development **expertise** from transactions with large biopharma

Know-how in life science research & development, biophysical and structure-based drug discovery

Strong financial, capital markets and legal **experience**

Looking ahead: Upcoming value drivers

2024

- **VIVIAD data readout** ✓
- **Strategic shift to kidney disease** ✓
- **VIVIAD kidney data at ASN** ✓
- **VIVA-MIND data readout** ✓

2025

- **MoA/biomarker data**
- **Orphan kidney pre-clinical data**
- **Start Ph. 2 DKD study[1]**
- **Potential to start small orphan disease study[1]**

2026+

- **Ph. 2 DKD study interim data**
  (~15 months post P2 initiation)
- **Ph. 2 DKD study full data**
  (~15 months post P2 interim)

[1] *Subject to funding / partnership*

Vivoryon: Phase 2 program confirms varoglutamstat as a leading compound for further development in kidney disorders including DKD

Groundbreaking discovery	**Inhibition of QPCTL reduces kidney inflammation and fibrosis**
Breakthrough clinical results	**Varoglutamstat – first in class QPCT/L inhibitor – shows a large and statistically significant improvement of eGFR versus placebo in two independent Phase 2 studies**
Outstanding commercial potential	**Substantial market opportunity in DKD with potential to prolong time before kidney replacement therapy – further potential in other kidney and liver indications**
Actionable clinical plan	**Completion of Phase 2 DKD program requires only one additional study**
Trusted organization	**Management with track record in fibrosis and business development**

QPCTL: iso-glutaminyl cyclase enzyme or glutaminyl peptide cyclotransferase-like protein; DKD: Diabetic Kidney Disease

Vivoryon Therapeutics N.V.

Halle (Saale)
Weinbergweg 22
06120 Halle (Saale), Germany

Munich
Franz-Josef-Delonge-Str. 5
81249 München, Germany

IR@vivoryon.com
+49 (0)345 555 99 00

www.vivoryon.com